Loading patent…
AssigneeGenzyme Corporation
InventorsJames Dodge, Lamya Shihabuddin, Catherine O’Riordan
Estimating the term…
This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject’s spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject’s spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the subject’s brain.
1-9. (canceled)
A method to treat amyotrophic lateral sclerosis (ALS) in a subject, comprising administering a recombinant neurotrophic viral vector comprising a therapeutic transgene to at least one ventricle of the brain, whereby said transgene is expressed in a therapeutically effective amount;
(canceled)
(canceled)
17-20. (canceled)
24-30. (canceled)
A method to treat amyotrophic lateral sclerosis in a human subject, comprising administering a recombinant AAV4 viral vector comprising a VEGF transgene to at least one ventricle of the brain selected from the group consisting of a lateral ventricle and the fourth ventricle, whereby said VEGF transgene is expressed in a therapeutically effective amount.
Dependencies are inferred from the claim text.